TY - GEN
T1 - Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis
AU - Christadoss, Premkumar
AU - Tüzün, Erdem
AU - Li, Jing
AU - Saini, Shamsher S.
AU - Yang, Huan
PY - 2008/6
Y1 - 2008/6
N2 - Mice deficient for complement factors C3, C4, or C5 are resistant to experimental autoimmune myasthenia gravis (EAMG). Acetylcholine receptor (AChR) immune lymph node cells (LNC) of C3 deficient mice produce less interleukin 6 (IL-6), and EAMG-resistant IL-6 deficient mice have less serum C3. Increased serum C1q-circulating immune complex (CIC) levels correlated with EAMG disease severity in RIIIS/J mice. The CIC promotes EAMG severity by stimulating the production of LNC IL-6, serum C1q, and C3 via FCγR interaction. Therefore, EAMG/MG could be treated by blocking the activation of classical complement pathway (CCP) and/or IL-6. Anti-C1q antibody administration before and following AChR immunization suppressed EAMG by reducing LNC IL-6 production and neuromuscular junction deposits of IgG, C3, and C5b-C9 complexes. Treatment with low dose (10 μg) of anti-C1q antibody twice a week for 4 weeks in mice with ongoing clinical EAMG reduced the clinical severity of disease and LNC IL-6 production. Therefore, inhibitors of CCP factors C1q, C2, or C4 could treat MG and would preserve the alternate complement pathway activation. Our goal is to tailor MG therapy using anti-C2/C4 reagents in combination, with or without anti-cytokine (e.g., anti-IL-6) reagents.
AB - Mice deficient for complement factors C3, C4, or C5 are resistant to experimental autoimmune myasthenia gravis (EAMG). Acetylcholine receptor (AChR) immune lymph node cells (LNC) of C3 deficient mice produce less interleukin 6 (IL-6), and EAMG-resistant IL-6 deficient mice have less serum C3. Increased serum C1q-circulating immune complex (CIC) levels correlated with EAMG disease severity in RIIIS/J mice. The CIC promotes EAMG severity by stimulating the production of LNC IL-6, serum C1q, and C3 via FCγR interaction. Therefore, EAMG/MG could be treated by blocking the activation of classical complement pathway (CCP) and/or IL-6. Anti-C1q antibody administration before and following AChR immunization suppressed EAMG by reducing LNC IL-6 production and neuromuscular junction deposits of IgG, C3, and C5b-C9 complexes. Treatment with low dose (10 μg) of anti-C1q antibody twice a week for 4 weeks in mice with ongoing clinical EAMG reduced the clinical severity of disease and LNC IL-6 production. Therefore, inhibitors of CCP factors C1q, C2, or C4 could treat MG and would preserve the alternate complement pathway activation. Our goal is to tailor MG therapy using anti-C2/C4 reagents in combination, with or without anti-cytokine (e.g., anti-IL-6) reagents.
KW - Autoimmunity
KW - Complement
KW - Experimental autoimmune myasthenia gravis
KW - Immune complex
KW - Myasthenia gravis
UR - http://www.scopus.com/inward/record.url?scp=45249122485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=45249122485&partnerID=8YFLogxK
U2 - 10.1196/annals.1405.009
DO - 10.1196/annals.1405.009
M3 - Conference contribution
C2 - 18567870
AN - SCOPUS:45249122485
SN - 9781573316873
T3 - Annals of the New York Academy of Sciences
SP - 210
EP - 219
BT - Myasthenia Gravis and Related Disorders 11th International Conference
PB - Blackwell Publishing Inc.
ER -